Cronos Group Inc
XMUN:7CI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cronos Group Inc
XMUN:7CI
|
CA |
|
D
|
Dexcom Inc
XBER:DC4
|
US |
|
B
|
Builders FirstSource Inc
SWB:B1F
|
US |
|
N
|
NETGEAR Inc
SWB:NGJ
|
US |
|
P
|
Plains GP Holdings LP
F:PG81
|
US |
Cronos Group Inc
Cronos Group is a cannabis company that grows, processes, and sells cannabinoid products. It makes dried flower, oils, vapes, and other cannabis-based consumer products, and it also works on hemp-derived ingredients and cannabinoid research. Its role is not retail storefronts; it sits upstream in the supply chain as a producer and brand owner. The company sells mainly to adult-use cannabis customers and medical cannabis patients, depending on the market. It also works with distributors, wholesalers, and retail chains that carry its brands. Cronos makes money by selling finished cannabis products and, in some cases, ingredients and intellectual property tied to cannabinoid development. What makes Cronos different is that it combines consumer cannabis brands with a science-focused approach to cannabinoids and product formulation. That gives it exposure to both packaged cannabis products and longer-term research into how cannabinoids can be used in wellness and medical settings. For investors, it is best understood as a branded cannabis producer whose business depends on product quality, regulation, and access to legal cannabis markets.
Cronos Group is a cannabis company that grows, processes, and sells cannabinoid products. It makes dried flower, oils, vapes, and other cannabis-based consumer products, and it also works on hemp-derived ingredients and cannabinoid research. Its role is not retail storefronts; it sits upstream in the supply chain as a producer and brand owner.
The company sells mainly to adult-use cannabis customers and medical cannabis patients, depending on the market. It also works with distributors, wholesalers, and retail chains that carry its brands. Cronos makes money by selling finished cannabis products and, in some cases, ingredients and intellectual property tied to cannabinoid development.
What makes Cronos different is that it combines consumer cannabis brands with a science-focused approach to cannabinoids and product formulation. That gives it exposure to both packaged cannabis products and longer-term research into how cannabinoids can be used in wellness and medical settings. For investors, it is best understood as a branded cannabis producer whose business depends on product quality, regulation, and access to legal cannabis markets.
Record quarter: Cronos reported record net revenue and record gross profit in Q1 2026, with adjusted EBITDA also improving year over year.
Canada strength: Spinach reached the #1 vape position in Canada for the first time, while edibles stayed #1 and flower share improved as supply constraints eased.
International momentum: Israel delivered its ninth straight record quarter, and other international markets posted 97% year-over-year growth, driven by Germany.
Balance sheet: Cronos ended the quarter with $822 million in cash and no debt, and the board authorized a new $50 million share repurchase program.
Growth pipeline: Management said GrowCo is now online, CanAdelaar is still expected to close in summer 2026, and the company remains optimistic about U.S. rescheduling, while staying selective on where to participate.
